Developer docs
API playgroundTry for free, no card

Search company profiles

DeepView Imaging

Full company profile

uuid00ss4nd

Namestring
DeepView Imaging
Legal namestring
Precision Prostate Consulting, LLC
Company typeenum
Private
Founded yearstring
-
Descriptiontext

DeepView Imaging, a service brand of Precision Prostate Consulting, LLC, is a private Maine-based company that delivers AI-powered second-opinion analysis of prostate MRI scans to patients and healthcare providers via a HIPAA-compliant, self-serve web platform. Its core product is the Prostate MRI Analysis Service, which leverages FDA-cleared, CE-marked, and UKCA-certified AI software (ProstatID, developed by partner Bot Image, Inc.) to analyze standard biparametric or multiparametric MRI scans in approximately 30 minutes, identifying and scoring suspicious lesions, generating AI-assisted PI-RADS assessments, producing 3D prostate segmentation, and delivering color-overlay DICOM visualizations plus a PDF diagnostic report. The company also provides a dedicated provider channel for urologists, radiologists, primary care physicians, and imaging centers, with potential for PACS integration and CPT reimbursement pathways.

The business operates on a direct-to-consumer pay-per-scan model with no referral requirement: $259 USD for a first analysis and $159 USD for subsequent analyses, with payment only collected on successful processing and HSA reimbursement available since the service is not covered by insurance or Medicare. The platform serves two primary patient segments — recently diagnosed patients seeking confirmation before treatment and active surveillance patients tracking longitudinal changes — while the provider channel extends the addressable buyer base to clinical professionals. Geographically, DeepView is positioned to serve the US, EU, and UK markets following its 2025 international regulatory clearances, though actual revenue scale, headcount, and unit volumes are not publicly disclosed.

Short descriptiontext

DeepView Imaging, a service brand of Precision Prostate Consulting, LLC, delivers AI-powered second-opinion prostate MRI analysis via a direct-to-consumer web platform for individual patients and a parallel channel for urologists, radiologists, primary care physicians, and imaging centers.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersKennebunk, United States
HQ citystring
Kennebunk
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prostate MRI analysis, AI medical imaging, radiology decision support, prostate cancer detection, medical image analysis
Industry4 codes
PRIMARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALADAI
Second Opinion & Expert Medical Review Platforms
Healthcare & Life Sciences/Telehealth Platforms/Employer-Sponsored Virtual Care Platforms
SIC code1 code
  • Services-Health Services8000
Product category
Prostate MRI AI Analysis
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Direct MRI Analysis Service
TypeOne Time License
Description

Direct-to-consumer paid service where patients or providers pay per MRI analysis. First analysis priced at $259 USD, subsequent analyses at $159 USD. Payment is only collected if the MRI is processed successfully. Includes detailed PDF diagnostic report and colorized DICOM overlay images. Service is out-of-pocket and not covered by insurance or Medicare, though receipts may be submitted for HSA reimbursement.

deepviewimaging.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Infrastructure, Personnel, Marketing or Sales, Operations
Pricing details2 tiers
1First MRI Analysis - $259 USD
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$259 USD for the first prostate MRI analysis. Includes detailed PDF diagnostic report and DICOM images with color overlays. Results delivered within approximately 30 minutes of submission.

deepviewimaging.com
2Subsequent MRI Analysis - $159 USD
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$159 USD for subsequent MRI analyses (for returning patients with prior analyses). Same deliverables included: PDF report and colorized DICOM overlays.

deepviewimaging.com
GTM typeB2C
B2C
Offering typeSoftware
Software
Core offering1 text field

DeepView Imaging operates a direct-access web platform that delivers AI-powered second-opinion analysis of prostate MRI scans. Using the FDA-cleared ProstatID™ AI engine, the service identifies suspicious lesions, assigns cancer probability scores, suggests PI-RADS ratings, and produces color-overlay DICOM visualizations plus a PDF diagnostic report within approximately 30 minutes. It is offered out-of-pocket to individual patients (no referral required) and is also positioned for healthcare providers such as urologists, radiologists, primary care physicians, and imaging centers seeking AI-assisted clinical decision support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 93.6% AUROC performance for prostate cancer identification vs ~85% for conventional MRI interpretation
+3 more records
Product overview1 text field

DeepView Imaging offers a single unified product: the Prostate MRI Analysis Service, which leverages ProstatID (by Bot Image, Inc.) as its underlying AI engine. The service enables patients and providers to upload prostate MRI scans for AI-powered second-opinion analysis, delivering detailed PDF diagnostic reports with color-overlay DICOM images within approximately 30 minutes. The company operates as a service of Precision Prostate Consulting, LLC, providing direct-to-consumer access to FDA-cleared, CE-marked, and UKCA-certified prostate MRI AI analysis.

Product and service1 record
1Prostate MRI Analysis Service
CategoryAI Prostate MRI Analysis
Description

AI-powered second-opinion analysis service for prostate MRI scans, delivering a detailed PDF diagnostic report with color-overlay DICOM visualizations and 3D prostate volume rendering within approximately 30 minutes of upload. Designed for individual patients (no referral required, out-of-pocket pay-per-use) and for healthcare providers (urologists, radiologists, primary care physicians, imaging centers) seeking AI-assisted clinical decision support for lesion detection, cancer probability scoring, PI-RADS assessment, and longitudinal surveillance tracking. Priced at $259 USD for the first analysis and $159 USD for subsequent analyses, HSA-eligible.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or Integration
Description

Bot Image, Inc. is the developer of ProstatID™, the FDA-cleared AI software used for DeepView Imaging's prostate MRI analysis. DeepView Imaging shares MRI image files (DICOM format) with Bot Image solely for the purpose of performing AI-powered analysis and generating patient reports. Bot Image is contractually obligated to use data only for analysis purposes, maintain appropriate security measures, and comply with applicable privacy laws. This is a core technology partnership where DeepView Imaging acts as a service provider/channel for the ProstatID technology.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global MRI vendor with AI-augmented reading tools and a broad radiology informatics portfolio. Comparable as an incumbent that could natively embed prostate MRI AI features in its installed base.

TypeDirect peer
Description

Developer of ProFound AI for breast and prostate cancer detection on MRI/CT. Comparable in FDA-cleared cancer-imaging AI and clinical decision-support positioning, with overlapping prostate MRI use cases.

TypeEmerging player
Description

AI radiology company with cleared products for chest X-ray, head CT, and musculoskeletal imaging, expanding into multi-modality diagnostic AI. Comparable in building clinically validated imaging-AI workflows for radiology decision support.

TypeBroad incumbent
Description

Major MRI scanner vendor with embedded AI interpretation tools across its imaging platforms. Comparable as an incumbent channel for prostate MRI workflows and a potential partner or competitor through native AI offerings.

5Nanox (formerly Zebra Medical Vision)
TypeEmerging player
Description

Imaging AI vendor (formerly Zebra Medical Vision, now under Nanox) offering AI-based detection and analytics across multiple imaging modalities. Comparable as a multi-modality radiology AI provider with regulatory clearances.

TypeDirect peer
Description

Direct-to-consumer AI-assisted full-body MRI screening service. Comparable in DTC go-to-market, AI-augmented imaging interpretation, and self-pay pricing model, though Ezra focuses on whole-body screening rather than prostate-specific second opinions.

TypeDirect peer
Description

Largest US outpatient imaging network, increasingly integrating AI (including prostate MRI) into radiology workflows. Comparable as a channel for prostate MRI AI interpretation at scale, though via in-clinic delivery rather than DTC.

TypeDirect peer
Description

Developer of ProstatID, the FDA-cleared prostate MRI AI engine that DeepView Imaging distributes as a service. It is the upstream technology provider and most direct comparable in product, though DeepView wraps it in a DTC consumer experience.

TypeEmerging player
Description

Korea-based medical AI company with FDA-cleared imaging AI products for cancer detection across mammography, chest X-ray, and other modalities. Comparable as an AI-oncologic-imaging peer expanding into global markets.

TypeEmerging player
Description

AI company focused on digital pathology and oncologic imaging. Comparable as an oncology-focused diagnostic AI vendor with FDA breakthrough designation, targeting cancer detection/characterization.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DeepView Imaging

Prostate MRI AI Analysisdeepviewimaging.com

DeepView Imaging, a service brand of Precision Prostate Consulting, LLC, delivers AI-powered second-opinion prostate MRI analysis via a direct-to-consumer web platform for individual patients and a parallel channel for urologists, radiologists, primary care physicians, and imaging centers.

What DeepView Imaging does

DeepView Imaging, a service brand of Precision Prostate Consulting, LLC, is a private Maine-based company that delivers AI-powered second-opinion analysis of prostate MRI scans to patients and healthcare providers via a HIPAA-compliant, self-serve web platform. Its core product is the Prostate MRI Analysis Service, which leverages FDA-cleared, CE-marked, and UKCA-certified AI software (ProstatID, developed by partner Bot Image, Inc.) to analyze standard biparametric or multiparametric MRI scans in approximately 30 minutes, identifying and scoring suspicious lesions, generating AI-assisted PI-RADS assessments, producing 3D prostate segmentation, and delivering color-overlay DICOM visualizations plus a PDF diagnostic report. The company also provides a dedicated provider channel for urologists, radiologists, primary care physicians, and imaging centers, with potential for PACS integration and CPT reimbursement pathways.

The business operates on a direct-to-consumer pay-per-scan model with no referral requirement: $259 USD for a first analysis and $159 USD for subsequent analyses, with payment only collected on successful processing and HSA reimbursement available since the service is not covered by insurance or Medicare. The platform serves two primary patient segments — recently diagnosed patients seeking confirmation before treatment and active surveillance patients tracking longitudinal changes — while the provider channel extends the addressable buyer base to clinical professionals. Geographically, DeepView is positioned to serve the US, EU, and UK markets following its 2025 international regulatory clearances, though actual revenue scale, headcount, and unit volumes are not publicly disclosed.

DeepView Imaging firmographics

Firmographics
Name
DeepView Imaging
Legal name
Precision Prostate Consulting, LLC
Website
https://deepviewimaging.com
Company type
Private
Operating status
Operating
Short description
DeepView Imaging, a service brand of Precision Prostate Consulting, LLC, delivers AI-powered second-opinion prostate MRI analysis via a direct-to-consumer web platform for individual patients and a parallel channel for urologists, radiologists, primary care physicians, and imaging centers.
Ownership category
akta.pro rank

DeepView Imaging industry classification

Industry
Product category
Prostate MRI AI Analysis
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALADAI
Second Opinion & Expert Medical Review Platforms
Healthcare & Life Sciences/Telehealth Platforms/Employer-Sponsored Virtual Care Platforms

Keywords

  • Prostate MRI analysis
  • AI medical imaging
  • Radiology decision support
  • Prostate cancer detection
  • Medical image analysis

Where DeepView Imaging is headquartered

Location

Headquarters

HQ city
Kennebunk
HQ country
United States
HQ region
North America

Offices1 record

Markets served

DeepView Imaging business model

Business model
GTM type
B2C
Offering type
Software
Cost components
Technology or R&D, Infrastructure, Personnel, Marketing or Sales, Operations

Revenue model

  1. Direct MRI Analysis Service: Direct-to-consumer paid service where patients or providers pay per MRI analysis. First analysis priced at $259 USD, subsequent analyses at $159 USD. Payment is only collected if the MRI is processed successfully. Includes detailed PDF diagnostic report and colorized DICOM overlay images. Service is out-of-pocket and not covered by insurance or Medicare, though receipts may be submitted for HSA reimbursement.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goFirst MRI Analysis - $259 USD
Unit PricingPay-as-you-goSubsequent MRI Analysis - $159 USD

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

DeepView Imaging product offering

Product offering

Core offering

DeepView Imaging operates a direct-access web platform that delivers AI-powered second-opinion analysis of prostate MRI scans. Using the FDA-cleared ProstatID™ AI engine, the service identifies suspicious lesions, assigns cancer probability scores, suggests PI-RADS ratings, and produces color-overlay DICOM visualizations plus a PDF diagnostic report within approximately 30 minutes. It is offered out-of-pocket to individual patients (no referral required) and is also positioned for healthcare providers such as urologists, radiologists, primary care physicians, and imaging centers seeking AI-assisted clinical decision support.

Product overview

DeepView Imaging offers a single unified product: the Prostate MRI Analysis Service, which leverages ProstatID (by Bot Image, Inc.) as its underlying AI engine. The service enables patients and providers to upload prostate MRI scans for AI-powered second-opinion analysis, delivering detailed PDF diagnostic reports with color-overlay DICOM images within approximately 30 minutes. The company operates as a service of Precision Prostate Consulting, LLC, providing direct-to-consumer access to FDA-cleared, CE-marked, and UKCA-certified prostate MRI AI analysis.

Differentiator

Problem solved

Functional benefit

Products and services

  • Prostate MRI Analysis Service AI-powered second-opinion analysis service for prostate MRI scans, delivering a detailed PDF diagnostic report with color-overlay DICOM visualizations and 3D prostate volume rendering within approximately 30 minutes of upload. Designed for individual patients (no referral required, out-of-pocket pay-per-use) and for healthcare providers (urologists, radiologists, primary care physicians, imaging centers) seeking AI-assisted clinical decision support for lesion detection, cancer probability scoring, PI-RADS assessment, and longitudinal surveillance tracking. Priced at $259 USD for the first analysis and $159 USD for subsequent analyses, HSA-eligible.

Quantifiable outcome

  • 93.6% AUROC performance for prostate cancer identification vs ~85% for conventional MRI interpretation
  • +3 more outcomes

Companies that use DeepView Imaging

Customer profile

Named customers2 records

Segments5 records

Ideal customer profiles3 records

DeepView Imaging technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

DeepView Imaging partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Bot Image, Inc.coreTechnology or IntegrationBot Image, Inc. is the developer of ProstatID™, the FDA-cleared AI software used for DeepView Imaging's prostate MRI analysis. DeepView Imaging shares MRI image files (DICOM format) with Bot Image solely for the purpose of performing AI-powered analysis and generating patient reports. Bot Image is contractually obligated to use data only for analysis purposes, maintain appropriate security measures, and comply with applicable privacy laws. This is a core technology partnership where DeepView Imaging acts as a service provider/channel for the ProstatID technology.

Scale indicators6 records

Recent moves3 records

Expansion highlights5 records

DeepView Imaging competitors and assessment

Company assessment

Broad incumbents

  • Siemens Healthineers: Global MRI vendor with AI-augmented reading tools and a broad radiology informatics portfolio. Comparable as an incumbent that could natively embed prostate MRI AI features in its installed base.
  • GE HealthCare: Major MRI scanner vendor with embedded AI interpretation tools across its imaging platforms. Comparable as an incumbent channel for prostate MRI workflows and a potential partner or competitor through native AI offerings.

Direct peers

  • iCAD: Developer of ProFound AI for breast and prostate cancer detection on MRI/CT. Comparable in FDA-cleared cancer-imaging AI and clinical decision-support positioning, with overlapping prostate MRI use cases.
  • Ezra: Direct-to-consumer AI-assisted full-body MRI screening service. Comparable in DTC go-to-market, AI-augmented imaging interpretation, and self-pay pricing model, though Ezra focuses on whole-body screening rather than prostate-specific second opinions.
  • RadNet: Largest US outpatient imaging network, increasingly integrating AI (including prostate MRI) into radiology workflows. Comparable as a channel for prostate MRI AI interpretation at scale, though via in-clinic delivery rather than DTC.
  • Bot Image: Developer of ProstatID, the FDA-cleared prostate MRI AI engine that DeepView Imaging distributes as a service. It is the upstream technology provider and most direct comparable in product, though DeepView wraps it in a DTC consumer experience.

Emerging players

  • Qure.ai: AI radiology company with cleared products for chest X-ray, head CT, and musculoskeletal imaging, expanding into multi-modality diagnostic AI. Comparable in building clinically validated imaging-AI workflows for radiology decision support.
  • Nanox (formerly Zebra Medical Vision): Imaging AI vendor (formerly Zebra Medical Vision, now under Nanox) offering AI-based detection and analytics across multiple imaging modalities. Comparable as a multi-modality radiology AI provider with regulatory clearances.
  • Lunit: Korea-based medical AI company with FDA-cleared imaging AI products for cancer detection across mammography, chest X-ray, and other modalities. Comparable as an AI-oncologic-imaging peer expanding into global markets.
  • Paige.AI: AI company focused on digital pathology and oncologic imaging. Comparable as an oncology-focused diagnostic AI vendor with FDA breakthrough designation, targeting cancer detection/characterization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

DeepView Imaging social profiles

Digital presence

DeepView Imaging compliance and trust

Trust signal

Compliance5 records

DeepView Imaging financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DeepView Imaging leadership team

Management profile

Number of profiles

DeepView Imaging funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DeepView Imaging M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DeepView Imaging

What does DeepView Imaging do?

DeepView Imaging operates a direct-access web platform that delivers AI-powered second-opinion analysis of prostate MRI scans. Using the FDA-cleared ProstatID™ AI engine, the service identifies suspicious lesions, assigns cancer probability scores, suggests PI-RADS ratings, and produces color-overlay DICOM visualizations plus a PDF diagnostic report within approximately 30 minutes. It is offered out-of-pocket to individual patients (no referral required) and is also positioned for healthcare providers such as urologists, radiologists, primary care physicians, and imaging centers seeking AI-assisted clinical decision support.

Is DeepView Imaging a public or private company?

DeepView Imaging is a private company. It is classified as unknown and is currently operating.

When was DeepView Imaging founded?

DeepView Imaging was founded in -1.

Where is DeepView Imaging based?

DeepView Imaging is headquartered in Kennebunk, United States, in the North America region.

How does DeepView Imaging make money?

One revenue line is on record: direct MRI Analysis Service.

Who are DeepView Imaging's main competitors?

Broad incumbents on record are Siemens Healthineers and GE HealthCare. Direct peers are iCAD, Ezra, RadNet and Bot Image. Emerging players are Qure.ai, Nanox (formerly Zebra Medical Vision), Lunit and Paige.AI.

Does DeepView Imaging have an API?

No public API is recorded for DeepView Imaging.

What industry is DeepView Imaging in?

DeepView Imaging's product category is Prostate MRI AI Analysis. Its primary akta.pro industry code is HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software, with a secondary code of HDAAAEAH, Medical Imaging AI. Its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales